Literature DB >> 17347310

Reversal of defective glucagon responses to hypoglycemia in insulin-dependent autoimmune diabetic BB rats.

Huarong Zhou1, Tao Zhang, Elizabeth Oseid, Jamie Harmon, Naoko Tonooka, R Paul Robertson.   

Abstract

The intraislet insulin hypothesis has been proposed to explain absent glucagon responses to hypoglycemia. Recently we directly confirmed this hypothesis by restoring glucagon secretion via provision of a pancreatic artery insulin infusion, which was switched off at the time of hypoglycemia in Wistar rats made diabetic by streptozotocin. The current study examined this hypothesis in a model of spontaneous, autoimmune diabetes, the insulin-dependent diabetic BB rat. The insulin switch-off signal restored the defective glucagon responses to hypoglycemia. However, the magnitude of the restored response was markedly less than that observed in control nondiabetic BB rats (4- to 5-month-old diabetic BB rats = 147 +/- 27; 2-month-old nondiabetic BB rats = 1038 +/- 112 pg/ml, peak delta; P < 0.0001). Because time was required for the BB rat to spontaneously develop diabetes, we asked whether the incomplete restoration of the glucagon response might be related to the animals' growth and development. This led us to compare the glucagon response to hypoglycemia in nondiabetic BB and Wistar rats at 2 and 4-5 months of age. We observed age-related deterioration of not only glucose tolerance and insulin sensitivity but also glucagon responses to hypoglycemia in both strains. There was no significant difference between the glucagon responses to hypoglycemia in age-matched nondiabetic BB rats and diabetic BB rats provided with the insulin switch-off signal. We conclude that defective glucagon responses to hypoglycemia in BB rats can be corrected by restoring regulation of alpha-cell function by insulin.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17347310     DOI: 10.1210/en.2006-1375

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  10 in total

1.  System-level control to optimize glucagon counterregulation by switch-off of α-cell suppressing signals in β-cell deficiency.

Authors:  Leon S Farhy; Anthony L McCall
Journal:  J Diabetes Sci Technol       Date:  2009-01

Review 2.  Optimizing reduction in basal hyperglucagonaemia to repair defective glucagon counterregulation in insulin deficiency.

Authors:  L S Farhy; A L McCall
Journal:  Diabetes Obes Metab       Date:  2011-10       Impact factor: 6.577

3.  Hypothalamic AMP-activated protein kinase activation with AICAR amplifies counterregulatory responses to hypoglycemia in a rodent model of type 1 diabetes.

Authors:  X Fan; Y Ding; S Brown; L Zhou; M Shaw; M C Vella; H Cheng; E C McNay; R S Sherwin; R J McCrimmon
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-04-08       Impact factor: 3.619

4.  Amplification of pulsatile glucagon counterregulation by switch-off of alpha-cell-suppressing signals in streptozotocin-treated rats.

Authors:  Leon S Farhy; Zhongmin Du; Qiang Zeng; Paula P Veldhuis; Michael L Johnson; Kenneth L Brayman; Anthony L McCall
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-06-24       Impact factor: 4.310

5.  Pancreatic network control of glucagon secretion and counterregulation.

Authors:  Leon S Farhy; Anthony L McCall
Journal:  Methods Enzymol       Date:  2009       Impact factor: 1.600

Review 6.  The search for the mechanism of early sympathetic islet neuropathy in autoimmune diabetes.

Authors:  G J Taborsky; Q Mei; D J Hackney; T O Mundinger
Journal:  Diabetes Obes Metab       Date:  2014-09       Impact factor: 6.577

7.  Loss of islet sympathetic nerves and impairment of glucagon secretion in the NOD mouse: relationship to invasive insulitis.

Authors:  G J Taborsky; Q Mei; D J Hackney; D P Figlewicz; R LeBoeuf; T O Mundinger
Journal:  Diabetologia       Date:  2009-10-02       Impact factor: 10.122

Review 8.  Management of Type 2 Diabetes: Current Strategies, Unfocussed Aspects, Challenges, and Alternatives.

Authors:  Swapnil P Borse; Abu Sufiyan Chhipa; Vipin Sharma; Devendra Pratap Singh; Manish Nivsarkar
Journal:  Med Princ Pract       Date:  2020-08-20       Impact factor: 1.927

9.  Somatostatin receptor type 2 antagonism improves glucagon and corticosterone counterregulatory responses to hypoglycemia in streptozotocin-induced diabetic rats.

Authors:  Jessica T Y Yue; Elena Burdett; David H Coy; Adria Giacca; Suad Efendic; Mladen Vranic
Journal:  Diabetes       Date:  2011-11-21       Impact factor: 9.461

10.  In situ electrophysiological examination of pancreatic α cells in the streptozotocin-induced diabetes model, revealing the cellular basis of glucagon hypersecretion.

Authors:  Ya-Chi Huang; Marjan S Rupnik; Negar Karimian; Pedro L Herrera; Patrick Gilon; Zhong-Ping Feng; Herbert Y Gaisano
Journal:  Diabetes       Date:  2012-10-05       Impact factor: 9.461

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.